<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2021-4258</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-4258</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Поиск дополнительных диагностических критериев предсердной кардиомиопатии у больных с изолированной формой фибрилляции предсердий</article-title><trans-title-group xml:lang="en"><trans-title>Additional diagnostic criteria for atrial cardiomyopathy in patients with lone atrial fibrillation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3694-3647</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полянская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyanskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Александровна Полянская - кандидат медицинских работ, доцент кафедры пропедевтики внутренних болезней № 2</p></bio><email xlink:type="simple">eapolyanskaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7003-5186</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козиолова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koziolova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Андреевна Козиолова - доктор медицинских работ, профессор, зав. кафедрой пропедевтики внутренних болезней № 2</p></bio><email xlink:type="simple">nakoziolova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет имени академика Е.А.Вагнера</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.A. Wagner Perm State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>16</day><month>02</month><year>2021</year></pub-date><volume>26</volume><issue>1</issue><fpage>4258</fpage><lpage>4258</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полянская Е.А., Козиолова Н.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Полянская Е.А., Козиолова Н.А.</copyright-holder><copyright-holder xml:lang="en">Polyanskaya E.A., Koziolova N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/4258">https://russjcardiol.elpub.ru/jour/article/view/4258</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить дополнительные диагностические критерии предсердной кардиомиопатии (ПК) I класса у больных c изолированной формой фибрилляции предсердий (ФП).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведено одномоментное нерандомизированное клиническое исследование. В течение 12 мес. было последовательно включено 170 стабильных пациентов в возрасте до 60 лет, из числа которых были отобраны 99 больных. Критерием включения в первую группу было наличие изолированной ФП при увеличении индексированного объема левого предсердия (ИОЛП) или правого предсердия по данным эхокардиографии без сердечно-сосудистых, бронхолегочных заболеваний, артериальной гипертензии и диагностических критериев хронической сердечной недостаточности (ХСН). Критерием включения во вторую группу было наличие ФП в сочетании с ХСН. Критерием включения в третью группу было наличие диагностических критериев ХСН (N-терминальный мозговой натрийуретический пептид (NT-proBNP) &gt;125 пг/мл) у больных с синусовым ритмом.</p><p>У всех больных определяли концентрацию NT-proBNP, растворимого стимулирующего фактора роста, экспрессируемого геном 2 (sST2), а также креатинин и цистатин С с расчетом скорости клубочковой фильтрации, тканевый ингибитор матриксных металлопротеиназ 1 типа (TIMP-1), нейтрофил-желатиназа ассоциированный липокалин (NGAL), проводили неинвазивную артериографию.</p></sec><sec><title>Результаты</title><p>Результаты. NT-proBNP, TIMP-1, NGAL как диагностические методы определения ПК I класса у больных с изолированной формой ФП при построении ROC-кривой показали неудовлетворительную клиническую значимость. У пациентов с ПК и ФП вне зависимости от наличия или отсутствия ХСН выявлено наличие прямой средней степени взаимосвязи между sST2 и ИОЛП (r=0,470, p=0,012) и прямой сильной корреляции между sST2 и NT-proBNP (r=0,726, p=0,004). Путем построения ROC-кривой для всех имеющихся значений показателя sST2 с шагом 1 нг/мл было получено его диагностическое значение в диапазоне &gt;5,0 нг/мл, но &lt;16 нг/мл (AUC=0,98).</p></sec><sec><title>Заключение</title><p>Заключение. Концентрация sST2 в крови в диапазоне от 5 до 16 нг/мл может быть рассмотрена как дополнительный диагностический критерий ПК I класса у больных c изолированной формой ФП с чувствительностью — 98%, специфичностью — 80%.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To determine additional diagnostic criteria for class I atrial cardiomyopathy (ACM) in patients with lone atrial fibrillation (AF).</p></sec><sec><title>Material and methods</title><p>Material and methods. This cross sectional non-randomized clinical study included 170 stable patients &lt;60 years of age, of which 99 patients were selected. The inclusion criteria in the first group were the presence of lone AF with increased left atrial (LAVI) or right atrial volume index according to echocardiography without cardiovascular and pulmonary diseases, hypertension, and diagnostic criteria for heart failure (HF). The inclusion criterion in the second group was combination of AF and HF. The inclusion criterion in the third group was diagnostic criteria for HF (N-terminal pro-brain natriuretic peptide &gt;125 ng/ml) in patients with sinus rhythm. In all patients, the concentration of NT-proBNP, a soluble stimulating growth factor 2 (sST2), as well as creatinine and cystatin C with calculation of the glomerular filtration rate, tissue inhibitor of matrix metalloproteinases-1 (TIMP1), and neutrophil gelatinase associated lipocalin (NGAL) was determined. Non-invasive angiography was performed.</p></sec><sec><title>Results</title><p>Results. According to ROC analysis, NT-proBNP, TIMP-1, NGAL as markers of class I ACM in patients with lone AF, showed unsatisfactory clinical significance. In patients with ACM and AF, regardless of the presence/ absence of HF, direct moderate relationship between sST2 and LAVI (r=0,470, p=0,012) and direct strong correlation between sST2 and NT-proBNP (r=0,726, p=0,004). Using ROC curve, for all available sST2 values, its diagnostic significance was obtained in the range from 5 to 16 ng/ml (AUC=0,98).</p></sec><sec><title>Conclusion</title><p>Conclusion. The blood concentration of sST2 in the range from 5 to 16 ng/ml can be considered as an additional diagnostic criterion for class I ACM in patients with lone AF with a sensitivity of 98% and a specificity of 80%.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>предсердная кардиомиопатия</kwd><kwd>фибрилляция предсердий</kwd><kwd>растворимый стимулирующий фактор роста</kwd><kwd>экспрессируемый геном 2</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial cardiomyopathy</kwd><kwd>atrial fibrillation</kwd><kwd>soluble stimulating growth factor 2</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. Journal of Arrhythmia. 2016;32(4):247-78. doi:10.1016/j.joa.2016.05.002.</mixed-citation><mixed-citation xml:lang="en">Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. Journal of Arrhythmia. 2016;32(4):247-78. doi:10.1016/j.joa.2016.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;ehaa612. doi:10.1093/eurheartj/ehaa612.</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;ehaa612. doi:10.1093/eurheartj/ehaa612.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Goudis CA, Kallergis EM, Kanoupakis EM, et al. Electrophysiological and Electroanato-mical Mapping of the Right Atrium in Persistent Atrial Fibrillation: Relation to Collagen Turnover. Pacing Clin Electrophysiol. 2015;38(9):1039-48. doi:10.1111/pace.12662.</mixed-citation><mixed-citation xml:lang="en">Goudis CA, Kallergis EM, Kanoupakis EM, et al. Electrophysiological and Electroanato-mical Mapping of the Right Atrium in Persistent Atrial Fibrillation: Relation to Collagen Turnover. Pacing Clin Electrophysiol. 2015;38(9):1039-48. doi:10.1111/pace.12662.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Oikanomou E, Zografos T, Papamikroulis G-A, et al. Biomarkers in Atrial Fibrillation and Heart Failure. Curr Med Chem. 2019;26(5):873-87. doi:10.2174/0929867324666170830100424.</mixed-citation><mixed-citation xml:lang="en">Oikanomou E, Zografos T, Papamikroulis G-A, et al. Biomarkers in Atrial Fibrillation and Heart Failure. Curr Med Chem. 2019;26(5):873-87. doi:10.2174/0929867324666170830100424.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Beyhoff N, Lohr D, Foryst-Ludwig A, et al. Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage. Hypertension. 2019;74(2):295-304. doi:10.1161/HYPERTENSIONAHA.119.12956.</mixed-citation><mixed-citation xml:lang="en">Beyhoff N, Lohr D, Foryst-Ludwig A, et al. Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage. Hypertension. 2019;74(2):295-304. doi:10.1161/HYPERTENSIONAHA.119.12956.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Полянская Е. А., Козиолова Н. А., Миронова С. В. Оценка стимулирующего фактор роста, экспрессируемого геном 2, как раннего маркера хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка у больных персистирующей формой фибрилляции предсердий. Российский кардиологический журнал. 2020;25(1):3705. doi:10.15829/1560-4071-2020-1-3705.</mixed-citation><mixed-citation xml:lang="en">Polyanskaya EA, Koziolova NA, Mironova SV. Evaluation of ST2 as an early marker of heart failure with a preserved left ventricular ejection fraction in patients with persistent atrial fibrillation. Russian Journal of Cardiology. 2020;25(1):3705. (In Russ.) doi:10.15829/1560-4071-2020-1-3705.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Villacorta H, Maisel A. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016;106(2):145-52. doi:10.5935/abc.20150151.</mixed-citation><mixed-citation xml:lang="en">Villacorta H, Maisel A. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016;106(2):145-52. doi:10.5935/abc.20150151.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li L-Y-F, Lou Q, Liu G-Z, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur J Pharmacol. 2020;881:173120. doi:10.1016/j.ejphar.2020.173120.</mixed-citation><mixed-citation xml:lang="en">Li L-Y-F, Lou Q, Liu G-Z, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur J Pharmacol. 2020;881:173120. doi:10.1016/j.ejphar.2020.173120.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Okar S, Kaypakli O, Sahin DY, Koc M. Fibrosis Marker Soluble ST2 Predicts Atrial Fibrillation Recurrence after Cryoballoon Catheter Ablation of Nonvalvular Paroxysmal Atrial Fibrillation. Korean Circ J. 2018;48(10):920-9. doi:10.4070/kcj.2018.0047.</mixed-citation><mixed-citation xml:lang="en">Okar S, Kaypakli O, Sahin DY, Koc M. Fibrosis Marker Soluble ST2 Predicts Atrial Fibrillation Recurrence after Cryoballoon Catheter Ablation of Nonvalvular Paroxysmal Atrial Fibrillation. Korean Circ J. 2018;48(10):920-9. doi:10.4070/kcj.2018.0047.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Leopold JA. The Central Role of Neutrophil Gelatinase-Associated Lipocalin in Cardiovascular Fibrosis. Hypertension. 2015;66(1):20-2. doi:10.1161/HYPERTENSIONAHA.115.05479.</mixed-citation><mixed-citation xml:lang="en">Leopold JA. The Central Role of Neutrophil Gelatinase-Associated Lipocalin in Cardiovascular Fibrosis. Hypertension. 2015;66(1):20-2. doi:10.1161/HYPERTENSIONAHA.115.05479.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Buonafine M, Martmez-Martmez E, Amador C, et al. Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol. 2018;115:32-8. doi:10.1016/j.yjmcc.2017.12.011.</mixed-citation><mixed-citation xml:lang="en">Buonafine M, Martmez-Martmez E, Amador C, et al. Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol. 2018;115:32-8. doi:10.1016/j.yjmcc.2017.12.011.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shaikh AY, Wang N, Yin X, et al. Relations of Arterial Stiffness and Brachial Flow-Mediated Dilation With New-Onset Atrial Fibrillation: The Framingham Heart Study. Hypertension. 2016;68(3):590-6. doi:10.1161/HYPERTENSIONAHA.116.07650.</mixed-citation><mixed-citation xml:lang="en">Shaikh AY, Wang N, Yin X, et al. Relations of Arterial Stiffness and Brachial Flow-Mediated Dilation With New-Onset Atrial Fibrillation: The Framingham Heart Study. Hypertension. 2016;68(3):590-6. doi:10.1161/HYPERTENSIONAHA.116.07650.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65(20):2239-51. doi:10.1016/j.jacc.2015.03.557.</mixed-citation><mixed-citation xml:lang="en">Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65(20):2239-51. doi:10.1016/j.jacc.2015.03.557.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zekavat SM, Roselli C, Hindy G, et al. Genetic Link Between Arterial Stiffness and Atrial Fibrillation. Circ Genom Precis Med. 2019;12(6):e002453. doi:10.1161/CIRCGEN.118.002453.</mixed-citation><mixed-citation xml:lang="en">Zekavat SM, Roselli C, Hindy G, et al. Genetic Link Between Arterial Stiffness and Atrial Fibrillation. Circ Genom Precis Med. 2019;12(6):e002453. doi:10.1161/CIRCGEN.118.002453.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
